Melanoma

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Staff July 21, 2022

Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand...

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Staff July 20, 2022

Portage now holds 100% ownership of iOx Therapeutics Ltd., buying out remainder of equity in exchange for PRTG stockWESTPORT, Conn.,...

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Staff July 19, 2022

Ad hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew...

Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

Staff July 14, 2022

Intratumoral injection of allogeneic pro-inflammatory dendritic cells (“ilixadencel”) substantially and sustainably enhanced an otherwise ineffective systemic anti CTLA-4 treatment in...

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

user February 4, 2021

CV8102 recommended dose identified; expansion trial to confirm safety, tolerability, and efficacy Trial expansion focuses on advanced melanoma, an indication of...

Melanoma

Sandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)

Portage Biotech Acquires Outstanding Minority Interest of Invariant Natural Killer T cell (iNKT) Agonist Platform

Novartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidance

Mendus AB: Mendus Publishes Preclinical Data Demonstrating Significant Anti-Tumor Synergies of Intratumoral Immune Priming with CTLA-4 Inhibition

CureVac Expands Lead RNA Cancer Program Phase 1 Trial in Advanced Melanoma

Vantive Chief Strategy Officer Joins Labviva Board

Senti Bio to Showcase SENTI-202 Clinical Data and Novel Logic Gated Gene Circuit Mechanism of Action in Oral and Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025

SPARK NS Selects Eight Projects to Receive Aggregate Funding of Up to $16 Million to Advance Academic Discoveries in Parkinson’s Disease from the Lab to the Clinic

Resmed Announces Small, Easy to Use Home Sleep Apnea Test, NightOwl™, Now Available Across the US

Precision Optics Enters into Main Purchase Agreement with Top Tier Aerospace Customer and Expands Program Backlog to $6.6 Million

You may have missed